KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

SGLT2 inhibition improves PI3Kα inhibitor-induced hyperglycemia: findings from preclinical animal models and from patients in the BYLieve and SOLAR-1 trials.

Manuel Ruiz Borrego, Yen-Shen Lu, Felipe Reyes-Cosmelli, Yeon Hee Park, Toshinari Yamashita, Joanne Chiu, Mario Airoldi, Nicholas Turner, Luis Fein, Farhat Ghaznawi, Jyotika Singh, Kristyn Pantoja, Christian Schnell, Murat Akdere, Stephen Chia

Breast Cancer Res Treat 208(1) 111-121

PMID39177931
PMCIDPMC11452482
DOI10.1007/s10549-024-07405-8
发表日期2024-08-23
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:图像复核确认至少一个 KM 面板含可见 No. at risk 表。
摘要

摘要

PURPOSE: Alpelisib plus fulvestrant demonstrated a significant progression-free survival benefit versus fulvestrant in patients with PIK3CA-mutated HR+ /HER2- advanced breast cancer (ABC) (SOLAR-1). Hyperglycemia, an on-target adverse effect of PI3Kα inhibition, can lead to dose modifications, potentially impacting alpelisib efficacy. We report data from preclinical models and two clinical trials (SOLAR-1 and BYLieve) on Sodium glucose cotransporter 2 inhibitor (SGLT2i) use to improve PI3Kα inhibitor-associated hyperglycemia. METHODS: Healthy Brown Norway (BN), mild diabetic Zucker diabetic fatty (ZDF), and Rat1-myr-p110α/HBRX3077 tumor-bearing nude rats treated with alpelisib were analyzed for glucose and insulin control with metformin and dapagliflozin (SGLT2i) and alpelisib efficacy. Hyperglycemia adverse events (AEs) were compared between patients receiving SGLT2i with alpelisib (n = 19) and a propensity score-matched cohort not receiving SGLT2i (n = 74) in both trials. RESULTS: Dapagliflozin and metformin in BN and ZDF rats treated with alpelisib normalized blood glucose and reduced insulin levels. No signs of ketosis or drug-drug interaction were observed when metformin and dapagliflozin was administered with alpelisib. Alpelisib antitumor efficacy was maintained when used with dapagliflozin in tumor-bearing rats. Compared with a matched set of patients without SGLT2i, patients receiving SGLT2i had 4.9 and 6.4 times lower rates of grade ≥ 3 hyperglycemia AEs and hyperglycemia AEs resulting in alpelisib dose adjustments, interruptions, or withdrawals, respectively, and a relative reduction in risk of experiencing these AEs (70.6% and 35.7%). CONCLUSION: These data suggest adding an SGLT2i can effectively manage hyperglycemia, resulting in fewer alpelisib dose modifications and discontinuations in patients with PIK3CA-mutated HR+ /HER2- ABC (SOLAR-1: NCT02437318; BYLieve: NCT03056755).

KM 提取结果

1 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure2 个面板

Fig. 5

Fig. 5 Time to first grade ≥ 3 hyperglycemia AE ( a ) and time to first hyperglycemia AE that led to dose adjustments, drug interruptions, or drug withdrawals ( b ) in patients in the SGLT2i and control cohorts. AE adverse event, SGLT2i sodium glucose cotransporter 2 inhibitor

A

Time to first grade ≥ 3 hyperglycemia AE

Fig. 5 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

Time to first hyperglycemia AE that led to dose adjustments, drug interruptions, or drug withdrawals

Fig. 5 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 BN rats treated with DAPA, MET, or ALP, double combination of ALP + MET or ALP + DAPA, or triple combination of ALP + DAPA + MET. a Blood glucose and plasma insulin levels. b Change in body weight and fed plasma β-hydroxybutyrate. c Study drug levels. d Blood glucose levels in BN rats treated sequentially with ALP combined with increasing dose of MET (n = 5) or ALP combined with MET and increasing doses of DAPA (n = 4). ALP alpelisib, ANOVA analysis of variance, BN Brown Norway, combo combination, DAPA dapagliflozin, MET metformin, po orally, qd once daily, SA single agent
非 KM Figure
Fig. 2Fig. 2 Blood glucose levels in ZDF rats treated sequentially with 12.5 mg/kg ( A ) and 30 and 40 mg/kg ( B ) dose of ALP combined with DAPA + MET. ALP alpelisib, BHB β-hydroxybutyrate, DAPA dapagliflozin, MET metformin, po orally, ZDF Zucker diabetic fatty
非 KM Figure
Fig. 3Fig. 3 Plasma insulin ( a ), ketone ( b ), lactate ( c ), and ALP ( d ) levels in blood of ZDF rats treated with ALP, double combination of ALP + MET, or triple combination of ALP + DAPA + MET. ALP alpelisib, BHB β-hydroxybutyrate, d day, DAPA dapagliflozin, MET metformin, po orally, qd once daily, ZDF Zucker diabetic fatty
非 KM Figure
Fig. 4Fig. 4 Antitumor efficacy of ALP or DAPA, double combination of ALP + DAPA, or triple combination of ALP + DAPA + MET in Rat1-myr-p110α ( a ) and HBRX3077 patient-derived ( b ) PIK3CA -mutated tumor-bearing nude rats. ALP alpelisib, DAPA dapagliflozin, MET metformin, po orally, qd once daily
非 KM Figure